$1.68
+0.01 (+0.60%)
Open$1.65
Previous Close$1.67
Day High$1.72
Day Low$1.63
52W High$3.54
52W Low$0.76
Volume—
Avg Volume762.0K
Market Cap105.89M
P/E Ratio—
EPS$-0.32
SectorBiotechnology
Analyst Ratings
Strong Buy
18 analysts
Price Target
+1,504.8% upside
Current
$1.68
$1.68
Target
$26.96
$26.96
$18.17
$26.96 avg
$35.46
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 68.45M | 35.55M | 33.75M |
| Net Income | -13,439,175 | 3.58M | 3.41M |
| Profit Margin | -19.6% | 10.1% | 10.1% |
| EBITDA | -14,905,588 | 5.92M | 5.34M |
| Free Cash Flow | — | 3.84M | 3.54M |
| Rev Growth | — | -9.4% | +19.8% |
| Debt/Equity | — | 0.12 | 0.13 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |